title: Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors.
abstract: The effects of both daily G-CSF administration and subsequent peripheral blood progenitor cell collection (PBPCC) by apheresis on 20 healthy adult donors were studied. All received daily G-CSF (filgrastim) 10 micrograms/kg for 5-7 days by subcutaneous injection. G-CSF administration was well tolerated, except for moderate bone pain and headache. Peak values of CD34+ cells were observed on days 5 (n = 12) or 6 (n = 8). In all donors a significant increase in CD3+, CD4+, CD8+, CD19+, and NK cells was observed on day 5 in relation to the baseline values. CD4/CD8 lymphocyte ratio was unmodified by G-CSF. None of the donors required a central venous line for PBPCC. Immediately after PBPCC, a platelet count below 100 x 10(9)/1 was observed in nine of 18 cases, although in all donors platelet counts were over 100 x 10(9)/1 7 days later. A lymphocytopenia on day 7 following PBPCC was observed, although there was a tendency to achieve baseline values 30-90 days after the procedure. Mean numbers ( +/- SD) of collected cells x 10(6)/kg after a median of two (1-4) apheresis sessions and a median of 20 1 (10-40) processed were: CD34+ 5.5 ( +/- 2.3), CD3+ 326 ( +/- 105), CD4+ 207 ( +/- 64), CD8+ 164 ( +/- 60), CD19+ 88 ( +/- 32), and NK cells 32 ( +/- 14). We conclude that G-CSF administration to healthy donors is a well-tolerated procedure which is associated with (a) obtaining a high number of hematopoietic progenitor cells, and (b) a significant increase in T, B, and NK cells in donors' blood. In addition, PBPCC by apheresis results in a moderate, rapidly reversible, and clinically irrelevant thrombocytopenia and a moderate lymphocytopenia, which tends to resolve within 3 months following the procedure.
authors.affiliation: Hematology Department, Hospital Clinic, University of Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Martínez
authors.forename: A
authors.initials: A
authors.lastname: Urbano-Ispizua
authors.forename: C
authors.initials: C
authors.lastname: Rozman
authors.forename: P
authors.initials: P
authors.lastname: Marín
authors.forename: R
authors.initials: R
authors.lastname: Mazzara
authors.forename: E
authors.initials: E
authors.lastname: Carreras
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.forename: J
authors.initials: J
authors.lastname: Sierra
authors.forename: J
authors.initials: J
authors.lastname: Briones
authors.forename: A
authors.initials: A
authors.lastname: Ordinas
authors.forename: E
authors.initials: E
authors.lastname: Montserrat
mesh_terms: D000293:Adolescent; D000328:Adult; D001781:Blood Component Removal; D001782:Blood Donors; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D016179:Granulocyte Colony-Stimulating Factor